Nanjing King-friend Biochemical Pharmaceutical Co Ltd (SHG:603707) — Market Cap & Net Worth
Market Cap & Net Worth: Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707)
Nanjing King-friend Biochemical Pharmaceutical Co Ltd (SHG:603707) has a market capitalization of $2.15 Billion (CN¥14.70 Billion) as of May 11, 2026. Listed on the SHG stock exchange, this China-based company holds position #6068 globally and #1341 in its home market, demonstrating a -2.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanjing King-friend Biochemical Pharmaceutical Co Ltd's stock price CN¥9.10 by its total outstanding shares 1615643839 (1.62 Billion). Analyse Nanjing King-friend Biochemical Pharmace (603707) cash conversion ratio to see how efficiently the company converts income to cash.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Nanjing King-friend Biochemical Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $1.73 Billion to $2.15 Billion (14.83% CAGR).
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.80x
Nanjing King-friend Biochemical Pharmaceutical Co Ltd's market cap is 0.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.80x
Nanjing King-friend Biochemical Pharmaceutical Co Ltd's market cap is 3.80 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.73 Billion | $1.11 Billion | $314.22 Million | 1.56x | 5.51x |
| 2018 | $1.50 Billion | $1.70 Billion | $424.55 Million | 0.88x | 3.54x |
| 2019 | $4.35 Billion | $2.47 Billion | $604.96 Million | 1.76x | 7.18x |
| 2020 | $4.81 Billion | $2.91 Billion | $806.12 Million | 1.65x | 5.97x |
| 2021 | $7.52 Billion | $3.69 Billion | $1.06 Billion | 2.04x | 7.10x |
| 2022 | $4.23 Billion | $3.71 Billion | $1.09 Billion | 1.14x | 3.88x |
| 2023 | $3.55 Billion | $3.93 Billion | -$189.45 Million | 0.90x | N/A |
| 2024 | $3.14 Billion | $3.92 Billion | $826.14 Million | 0.80x | 3.80x |
Competitor Companies of 603707 by Market Capitalization
Companies near Nanjing King-friend Biochemical Pharmaceutical Co Ltd in the global market cap rankings as of May 11, 2026.
Key companies related to Nanjing King-friend Biochemical Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #498 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #538 globally with a market cap of $49.29 Billion USD ( CN¥336.81 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #571 globally with a market cap of $45.88 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #654 globally with a market cap of $40.57 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #498 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.29 Billion | CN¥52.80 |
| #571 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.27 |
| #654 | Haleon plc | NYSE:HLN | $40.57 Billion | $9.11 |
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's market cap moved from $1.73 Billion to $ 2.15 Billion, with a yearly change of 14.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.15 Billion | +0.78% |
| 2025 | CN¥2.13 Billion | -31.95% |
| 2024 | CN¥3.14 Billion | -11.53% |
| 2023 | CN¥3.55 Billion | -16.14% |
| 2022 | CN¥4.23 Billion | -43.78% |
| 2021 | CN¥7.52 Billion | +56.22% |
| 2020 | CN¥4.81 Billion | +10.80% |
| 2019 | CN¥4.35 Billion | +188.88% |
| 2018 | CN¥1.50 Billion | -13.08% |
| 2017 | CN¥1.73 Billion | -- |
End of Day Market Cap According to Different Sources
On May 10th, 2026 the market cap of Nanjing King-friend Biochemical Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.15 Billion USD |
| MoneyControl | $2.15 Billion USD |
| MarketWatch | $2.15 Billion USD |
| marketcap.company | $2.15 Billion USD |
| Reuters | $2.15 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochlo… Read more